Rosen Law Firm Encourages Neumora Therapeutics Investors to Take Action Before Important Deadline in Securities Lawsuit

ROSEN GLOBAL INVESTOR COUNSEL ENCOURAGES NEUMORA THERAPEUTICS INC INVESTORS TO SECURE COUNSEL BEFORE THE MARCH 22, 2023 DEADLINE IN THE SECURITIES CLASS ACTION LAWSUIT

New York, NY - (GLOBE NEWSWIRE) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Neumora Therapeutics Inc (NASDAQ: NRTR) securities between March 23, 2021 and February 2, 2023, inclusive, of the important March 22, 2023 lead plaintiff deadline in the securities class action lawsuit.

So, what's the story? On February 2, 2023, the Company announced that it would be delaying the initiation of its Phase 3 clinical trial for NRTR-101, citing "unforeseen challenges." The news sent shares plummeting, allegedly causing significant losses to investors.

The Rosen Law Firm urges investors to secure counsel and take action to protect their rights. If you purchased Neumora Therapeutics Inc securities between March 23, 2021 and February 2, 2023, inclusive, and suffered losses, you may be entitled to join the case and recover your losses.

The lawsuit alleges that Neumora Therapeutics Inc made false and misleading statements about the Company's business and prospects. The case seeks to recover losses sustained by investors who purchased the Company's securities during the class period.

If you are a Neumora Therapeutics Inc investor and would like to join the lawsuit, please contact the Rosen Law Firm's Managing Partner, Laurence Rosen, at lrosen@rosenlegal.com or 434-286-2315. The deadline to file the lawsuit is March 22, 2023. A class action lawsuit has already been filed. If you are a member of the class, you may be able to participate in the lawsuit and potentially recover your losses. You may also be able to join the lawsuit by providing information about your purchase of Neumora Therapeutics Inc securities.